Axonopathy is a common and early phase in neurodegenerative and traumatic CNS diseases. Recent work suggests that amyloid β (Aβ) produced from amyloid precursor protein (APP) may be a critical downstream mediator of CNS axonopathy in CNS diseases, particularly those associated with hypoxia. We critically tested this hypothesis in an adult retinal explant system that preserves the three-dimensional organization of the retina while permitting direct imaging of two cardinal features of early-stage axonopathy: axonal structural integrity and axonal transport capacity. Using this system, we found via pharmacological inhibition and genetic deletion of APP that production of Aβ is a necessary step in structural compromise of retinal ganglion cell (RGC) axons induced by the disease-relevant stressor hypoxia. However, identical blockade of Aβ production was not sufficient to protect axons from associated hypoxia-induced reduction in axonal transport. Thus, Aβ mediates distinct facets of hypoxia-induced axonopathy and may represent a functionally selective pharmacological target for therapies directed against early-stage axonopathy in CNS diseases.
Introduction
Axonopathy, encompassing compromise of both axonal structure and function, is an early consequence of stress across a broad range of central neurons and neuropathological conditions (Coleman, 2005) . While clearly associated with physical trauma to the nervous system (Rotshenker, 2011) , axonopathy has also been increasingly appreciated as an early event in neurodegeneration in neurological disorders including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and glaucoma (Coleman, 2005; Morfini et al., 2009) . Common features of compromised axonal structure include the development of axonal varicosities, accumulation of organelles, and loss of synaptic contacts, whereas deficits in transport capacity is a core consequence of impaired axonal function. However, the pathways mediating such structural and functional compromise, and whether these pathways are intersecting or distinct, remain under investigation.
A growing body of evidence has implicated the production of amyloid beta (Aβ) from amyloid precursor protein (APP) as a common pathway associated with axonopathy. While Aβ has been studied most extensively in relation to AD (Hardy & Selkoe, 2002) , aberrant processing through this cascade has now also been reported in axonopathic diseases such as glaucoma (Yoneda et al., 2005) , multiple sclerosis (Ferguson et al., 1997) , ALS (Calingasan et al., 2005) , epilepsy (Borges et al., 2003) , stroke (Ohgami et al., 1992) , HIV-dementia (Raja et al., 1997), Creutzfeld-Jakob disease (Liberski & Budka, 1999) , and traumatic brain and optic nerve injury (Olsson et al., 2004; Reichard et al., 2004) . Aβ itself impairs axonal structure and function in a variety of experimental paradigms (Kasa et al., 2000; Pike et al., 1992; Stokin et al., 2005) , and blockade of the enzymes necessary for Aβ production from APP (BACE1 and the γ-secretase complex (Hardy and Selkoe, 2002; Scheuner et al., 1996; Vassar et al., 1999) protects central axons from diverse stressors (Farah et al., 2011; Nikolaev et al., 2009; Yoon et al., 2006; Jurynczyk et al., 2005) . Together, these data imply a broad role for Aβ as an effector of axonopathy across CNS degenerative diseases.
Such a role for Aβ would have particular relevance in the setting of CNS hypoxia. Hypoxia has long been known to induce both structural and functional axonopathy (Def Webster & Ames, 1965; Ochs & Ranish, 1970) , and the enzymatic pathway necessary for Aβ production is sensitive to tissue oxygen status (Peers et al., 2009) . CNS hypoxia in fact predisposes central neurons to degeneration in well-studied diseases like Alzheimer's and optic neuropathy (Grimm & Willmann, 2012; Zlokovic, 2011) , and such hypoxia-induced stress mechanisms as hypoxia-inducible factor-mediated pathways (Koh & Powis, 2012) , heat-shock-factor-mediated pathways (Baird et al., 2006; Shen et al., 2005) , and the unfolded protein response (Kim et al., 2008) are now understood to be central to the protein homeostasis defense mechanisms triggered in a wide range of neurodegenerative and neuroinflammatory conditions in the CNS (Powers et al., 2009; Mehta et al., 2009 ). Thus, elucidating hypoxia-activated axonopathic mechanisms likely to intersect with those in CNS disease remains an important goal.
Therefore, we sought here to test critically the hypothesis that Aβ is a critical downstream effector of hypoxic stress on central axons, Neurobiology of Disease 77 (2015) 94-105 
